Accent Microcell Limited (ACCENTMIC)
H1 FY27 results
Accent Microcell Limited reported H1 FY27 results on 14 Oct 2026: revenue ₹175 Cr (+25.4% year on year, -16.7% on the previous half-year), and net profit ₹31.1 Cr (+72.2% year on year); the operating margin was 23.6%.
| H1 FY27 (₹ Cr) | Value | YoY vs H1 FY26 | vs prev. half |
|---|---|---|---|
| Revenue | ₹175 | +25.4% | -16.7% |
| Operating profit | ₹41.3 | +72.9% | +25.3% |
| Net profit | ₹31.1 | +72.2% | +19.7% |
| EPS (₹) | 12.97 | +66.7% | +20.7% |
| Operating margin | 23.6% | — | — |
- Profit +30% above its own trend
- Operating margin expanded 649 bps YoY
Quality of profit: of pre-tax profit of ₹41.4 Cr, ₹38.8 Cr (94%) came from the core business and the rest from other income and one-off items. Core profit (operating profit less interest and depreciation) moved +80.9% year on year.
Against its own trend: net profit of ₹31.1 Cr was +29.5% against the ₹24.0 Cr its recent growth pointed to (above trend). This is a statistical baseline, not an analyst estimate.
Share price since the results: +1.4% (close before the filing to the latest close).
ACCENTMIC delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 64.2% of the ACCENTMIC shares traded on NSE were taken to delivery, against the stock's own 20-session average of 70.9%. That is close to its usual level.
Delivery in the last 5 sessions: 68.7% · 67.8% · 57.4% · 75.5% · 64.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Accent Microcell released its H1 FY27 investor presentation, reporting revenue from operations of ₹174.83 Cr (₹17,483.09 lakh), up 25.4% YoY. Profit after tax jumped 72.2% YoY to ₹31.12 Cr (₹3,111.60 lakh), while EBITDA rose 65% YoY to ₹43.90 Cr with an EBITDA margin of 25.11% (up 609 bps). Premium products' share in revenue increased by 304 bps YoY to 13.52%, and exports constituted 72.34% of revenue. Unit III at Nayka, Kheda is currently under commissioning with Phase 1 adding 2,800 MTPA capacity.
- H1 FY27 Revenue from operations reached ₹174.83 Cr, up 25.4% YoY
- PAT surged 72.2% YoY to ₹31.12 Cr with EBITDA climbing 65% YoY to ₹43.90 Cr
- EBITDA margin expanded by 609 bps YoY to 25.11%
- Export revenue accounted for 72.34% of total revenue, up 1,415 bps YoY
- Unit III Phase 1 trial runs underway, adding 2,800 MTPA capacity targeting ₹650–700/kg realizations
Accent Microcell reported standalone revenue from operations of ₹174.83 Cr for the half-year ended September 30, 2026, marking a 25.4% YoY increase compared to ₹139.37 Cr in H1 FY26. Standalone net profit surged 72.2% YoY to ₹31.12 Cr from ₹18.07 Cr, aided by lower finance costs and improved operational scale. Basic EPS improved to ₹12.97 compared to ₹7.84 in the prior-year period. Capital work-in-progress expanded to ₹134.66 Cr from ₹101.80 Cr in March 2026, driven by ongoing capacity additions.
- Revenue from operations grew 25.4% YoY to ₹17,483.09 lakhs for H1 ended Sep 30, 2026
- Net profit surged 72.2% YoY to ₹3,111.60 lakhs compared to ₹1,806.82 lakhs in H1 FY26
- Basic and diluted EPS grew to ₹12.97 per share from ₹7.84 per share in the year-ago period
- Capital work-in-progress increased to ₹13,466.21 lakhs as of Sep 30, 2026, compared to ₹10,179.77 lakhs as of Mar 31, 2026
- Confirmed zero deviations in the utilization of Rights Issue proceeds (₹3,977.13 lakhs raised)
Accent Microcell reported standalone revenue from operations of ₹174.83 Cr for the half-year ended September 30, 2026, marking a 25.4% YoY increase compared to ₹139.37 Cr in H1 FY26. Standalone net profit surged 72.2% YoY to ₹31.12 Cr from ₹18.07 Cr, aided by lower finance costs and improved operational scale. Basic EPS improved to ₹12.97 compared to ₹7.84 in the prior-year period. Capital work-in-progress expanded to ₹134.66 Cr from ₹101.80 Cr in March 2026, driven by ongoing capacity additions.
- Revenue from operations grew 25.4% YoY to ₹17,483.09 lakhs for H1 ended Sep 30, 2026
- Net profit surged 72.2% YoY to ₹3,111.60 lakhs compared to ₹1,806.82 lakhs in H1 FY26
- Basic and diluted EPS grew to ₹12.97 per share from ₹7.84 per share in the year-ago period
- Capital work-in-progress increased to ₹13,466.21 lakhs as of Sep 30, 2026, compared to ₹10,179.77 lakhs as of Mar 31, 2026
- Confirmed zero deviations in the utilization of Rights Issue proceeds (₹3,977.13 lakhs raised)
Accent Microcell has placed a turnkey purchase order with Inox Wind Limited for a 4.45 MW Wind Turbine Generator (WTG) on August 12, 2026. The project is designed for captive consumption to offset electricity costs at Plant-I, Plant-II, and the upcoming Phase-I of Plant-III. The investment will be funded through a mix of internal accruals and borrowings, aiming to improve operating profit margins. This move aligns with the company's strategy to support its 100%+ capacity expansion at Unit 3 with cost-efficient infrastructure.
- Placed a purchase order for a 4.45 MW Wind Turbine Generator on August 12, 2026
- Turnkey installation contract awarded to Inox Wind Limited
- Captive power will support existing Plant-I, Plant-II, and upcoming Plant-III (Phase-I)
- Funding to be sourced from internal accruals and borrowings against a net worth of ₹276 Cr
- Aims to improve operating margins (17.2% in Sep 2025) by reducing monthly electricity bills
Accent Microcell Limited concluded its 14th Annual General Meeting on July 31, 2026, with shareholders unanimously approving all nine proposed resolutions. Key approvals include the adoption of FY26 audited financial statements and the declaration of a final dividend for the year. The voting results showed 100% support from the 57 participating members, representing 1,56,03,050 shares. Additionally, the board saw the re-appointment of Mr. Vinod Manibhai Patel as Whole Time Director and the appointment of Ms. Pooja Dharmesh Shah as an Independent Director.
- 100% of the 1,56,03,050 votes cast were in favor of all nine resolutions, including dividend declaration.
- 57 members participated in the voting process, with 55 using remote e-voting and 2 voting during the AGM.
- Shareholders ratified the appointment of Ms. Pooja Dharmesh Shah as an Independent Director.
- The re-appointment and remuneration of Mr. Vinod Manibhai Patel as Whole Time Director was approved.
- The voting cut-off date was July 24, 2026, for the meeting held on July 31, 2026.
Accent Microcell Limited concluded its 14th Annual General Meeting on July 31, 2026, where shareholders approved all proposed resolutions. A final dividend of ₹1 per equity share (10% of face value) was declared for FY26. The meeting confirmed the re-appointment of the core leadership team, including the Executive Chairman and Managing Director, ensuring management continuity. Additionally, a new Independent Director was appointed for a five-year term ending in 2031.
- Approved a final dividend of ₹1 per fully paid-up equity share of ₹10 each.
- Re-appointed four key executive directors, including the Chairman and Managing Director, to maintain leadership stability.
- Appointed Ms. Pooja Dharmesh Shah as an Independent Director for a 5-year term from July 2026 to July 2031.
- Confirmed that the Auditor's Report for FY26 contained no qualifications or adverse remarks.
- Remote e-voting was conducted between July 28 and July 30, 2026, with all resolutions passed by requisite majority.
Accent Microcell Limited concluded its 14th Annual General Meeting on July 31, 2026, where shareholders approved all proposed resolutions. Key outcomes include the declaration of a final dividend of ₹1 per equity share for FY 2025-26 and the re-appointment of the core leadership team, including the Executive Chairman and Managing Director. The company also appointed Ms. Pooja Dharmesh Shah as an Independent Director for a five-year term. Notably, the auditors issued no qualifications or adverse remarks regarding the company's financial statements for the year ended March 31, 2026.
- Approved a final dividend of ₹1 per fully paid-up equity share of ₹10 each for FY 2025-26
- Re-appointed four key executive directors, including Chairman Vasant Vadilal Patel and MD Ghanshyam Arjanbhai Patel
- Appointed Ms. Pooja Dharmesh Shah as an Independent Director for a 5-year term ending July 5, 2031
- Confirmed no qualifications or adverse remarks from auditors on the FY26 financial statements
- The meeting concluded on July 31, 2026, with all resolutions passed by requisite majority
Financial Performance
Revenue Growth by Segment
Revenue from operations grew 8% YoY to INR 264.58 Cr in FY25 from INR 245.50 Cr in FY24. Microcrystalline Cellulose (MCC) remains the core segment contributing approximately 85% of revenue, while premium excipients and other products like CCS and CMS contribute the remaining 15%.
Geographic Revenue Split
Exports contributed 59.06% of Total Operating Income (TOI) in FY24, down from 63.54% in FY23. Key international markets include the U.S.A., Australia, U.K., and Russia. Domestic sales account for approximately 40.94% of revenue, primarily serving the non-spray dry material market.
Profitability Margins
Net Profit Ratio stood at 12.50% in FY25, a slight improvement from 12.29% in FY24. Profit After Tax (PAT) rose 10% to INR 33.06 Cr in FY25 from INR 30.17 Cr. Management targets 25% PAT margins for premium products like Croscarmellose Sodium (CCS).
EBITDA Margin
EBITDA grew 12% to INR 48.32 Cr in FY25, reflecting an EBITDA margin of approximately 18.26%. Management has guided for a weighted average EBITDA margin of 20-22% as the product mix shifts toward premium excipients in Unit 3.
Capital Expenditure
The company utilized proceeds from a December 2023 IPO of INR 78.40 Cr to fund capacity expansions. Unit 3 Phase 1 (2,400 MTPA) is focused on premium products, while Phase 2 (12,000 MTPA) is expected to be operational by July 2026.
Credit Rating & Borrowing
CARE Ratings reaffirmed 'CARE BBB+; Stable / CARE A2' in March 2025. Borrowing costs are low as the Debt-to-Equity ratio improved to 0.01x in FY25 following the repayment of the Cash Credit facility.
Operational Drivers
Raw Materials
Wood pulp is the primary raw material, representing the largest portion of the cost structure. Other materials include chemicals for the production of CCS, CMS, and SSG.
Import Sources
The company imports a significant portion of its raw materials, though specific countries of origin are not disclosed in available documents. Operations are based in Pirana and Dahej (SEZ), Gujarat.
Key Suppliers
Not disclosed in available documents; however, the company maintains multi-year business relationships with key suppliers to ensure supply chain stability.
Capacity Expansion
Current installed capacity increased from 9,200 MTPA to 12,000 MTPA in FY25. Planned expansion includes Unit 3 Phase 1 (2,400 MTPA for premium products) and Phase 2 (12,000 MTPA for MCC), targeting a total capacity exceeding 24,000 MTPA by July 2026.
Raw Material Costs
Raw material costs are susceptible to global wood pulp price volatility. The company uses strategic inventory reserves and long-term procurement contracts to mitigate the impact of price fluctuations on its 18.26% EBITDA margin.
Manufacturing Efficiency
ROCE improved to 22.40% in FY25 from 21.20% in FY24, indicating efficient capital utilization. Capacity utilization is expected to reach 70% for new units within the first full year of operation.
Logistics & Distribution
Not disclosed in absolute INR; however, the company utilizes a distributor-led model for both domestic and export markets to manage distribution costs.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be driven by a 100%+ capacity expansion at Unit 3 and a strategic shift toward premium excipients (CCS, CMS, SSG) which command 3x the pricing of standard MCC. The company is also launching R&D-led products like SMCC and MCC Spheres to capture higher-margin pharmaceutical segments.
Products & Services
Microcrystalline Cellulose (MCC), Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG), Carboxymethyl Cellulose (CMS), SMCC, Cellulose powder, and MCC Spheres.
Brand Portfolio
Accent Microcell Limited (Corporate Brand).
New Products/Services
New R&D products include SMCC, Cellulose powder, MCC Spheres, and Co-processed MCC, which are expected to contribute to the targeted 20-22% EBITDA margin.
Market Expansion
Expansion is focused on increasing the footprint in the U.S.A., Russia, and the U.K., alongside domestic growth in high-growth sectors like nutraceuticals and cosmetics.
Market Share & Ranking
The company is a specialized player in the fragmented MCC market, competing with both organized players like Sigachi and unorganized manufacturers.
External Factors
Industry Trends
The pharmaceutical excipient industry is shifting toward high-functionality co-processed excipients. The company is positioning itself by expanding into premium grades to move away from the commoditized 85% MCC revenue base.
Competitive Landscape
The market is highly fragmented. Key competitors include Sigachi Industries and various unorganized players. Competition is based on spray-dry technology vs. non-spray dry material.
Competitive Moat
The company's moat is built on 20 years of specialization in MCC, certified manufacturing facilities (ISO, GMP, US-DMF), and a diversified global distributor network. Sustainability is driven by the high entry barriers of pharmaceutical quality audits.
Macro Economic Sensitivity
The business is sensitive to global pharmaceutical demand and trade restrictions. A 5-6% base industry growth rate for MCC is expected, which can rise to 7-8% during peer supply disruptions.
Consumer Behavior
Increased demand for high-growth sectors like nutraceuticals and food & beverages is driving the need for specialized cellulose-based excipients.
Geopolitical Risks
Geopolitical tensions and trade restrictions in key export markets like Russia and the U.S.A. could impact volume-backed growth.
Regulatory & Governance
Industry Regulations
Operations must comply with US-DMF, Kosher, Halal, and GMP certifications. Evolving international regulatory frameworks for pharmaceutical ingredients increase operational complexity and compliance costs.
Environmental Compliance
The company maintains ISO 14001:2015 standards and complies with FSSC 22000 and HACCP for food safety and environmental management.
Taxation Policy Impact
The Dahej unit is located in a Special Economic Zone (SEZ), providing various exemptions and deductions in direct and indirect tax payments.
Legal Contingencies
Not disclosed in available documents; the company maintains an internal audit firm to ensure adherence to regulatory compliance.
Risk Analysis
Key Uncertainties
Volatility in raw material prices (wood pulp) and energy costs could impact margins by 2-3%. Peer capacity issues (e.g., Sigachi) provide temporary growth but represent long-term competitive risks.
Geographic Concentration Risk
59.06% of revenue is from exports, creating high sensitivity to international trade policies and global logistics stability.
Third Party Dependencies
Dependence on distributors for both domestic and export sales; however, the company has an in-house business development team to manage these relationships.
Technology Obsolescence Risk
The shift from non-spray dry to spray-dry technology in the domestic market (currently 70-80% non-spray dry) represents a technology transition risk the company is addressing through Unit 3.
Credit & Counterparty Risk
Receivables Turnover Ratio was 4.46x in FY25. The company offers liberal payment terms to maintain customer loyalty, which could impact working capital if not managed.
